Evalution of the neurospecific autoantibodies level in patients with Covid-19: preliminary report
| Autor: | E. V. Volkov, A. A. Fil, T. A. Dotdaeva, V. A. Baturin, M. V. Kostrovskaya, E. V. Grudina, M. V. Baturina, V. V. Fisher |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Autoantibody General Medicine S100 protein Endocrinology nervous system Dopamine Dopamine receptor Internal medicine medicine NMDA receptor In patient business medicine.drug |
| Zdroj: | Medical news of the North Caucasus. 16 |
| ISSN: | 2073-8137 |
| DOI: | 10.14300/mnnc.2021.16017 |
| Popis: | In severe COVID-19 patients the blood level of autoantibodies (IgG) to neurospecific proteins was determined. It defined the marked increase in autoantibodies to peripheral myelin protein, protein lipid protein, S100 protein, type 2 dopamine receptors and dopamine. At the same time, it was designate the relationship between the levels of autoantibodies to the S100 protein and NMDA receptors. High levels of specific IgG to SARS-CoV-2 S-Trimer Protein coincided with high levels of autoantibodies to S100 protein and NMDA receptors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|